
Annual report 2025
added 02-24-2026
Alphatec Holdings Revenue 2011-2026 | ATEC
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Alphatec Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 764 M | 612 M | 482 M | 351 M | 243 M | 145 M | 113 M | 91.7 M | 102 M | 120 M | 185 M | 207 M | 205 M | 196 M | 198 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 764 M | 91.7 M | 268 M |
Quarterly Revenue Alphatec Holdings
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 186 M | 169 M | - | 151 M | 146 M | 138 M | - | 118 M | 117 M | 109 M | - | 89.8 M | 84.2 M | 70.9 M | - | 62.9 M | 62.2 M | 44.1 M | - | 41.2 M | 29.6 M | 30.1 M | - | 29.2 M | 27.3 M | 24.6 M | - | 23 M | 22 M | 21.3 M | - | 23.1 M | 24.4 M | 28 M | 27.1 M | 26.7 M | 32.2 M | 34.2 M | 34.8 M | 31.7 M | 46.6 M | 48.6 M | 53.6 M | 51 M | 53.2 M | 49.2 M | 53.1 M | 50.2 M | 51 M | 50.4 M | 52.7 M | 46.8 M | 48.2 M | 48.5 M | 49.5 M | 47.6 M | 50.9 M | 49.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 186 M | 21.3 M | 59.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.58 | -0.11 % | $ 122 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.0 | -0.58 % | $ 1.62 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 90.43 | 2.07 % | $ 12.2 B | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.11 | -2.88 % | $ 258 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 36.38 | -0.98 % | $ 5.42 K | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.8 | -5.53 % | $ 1.09 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.25 | -0.64 % | $ 712 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 54.48 | 0.63 % | $ 1.6 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.03 | 3.35 % | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.52 | -0.13 % | $ 2.97 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.77 | -2.04 % | $ 69 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.82 | -0.75 % | $ 371 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 86.33 | 0.06 % | $ 111 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.42 | -1.16 % | $ 128 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.67 | -4.85 % | $ 28 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
4 B | $ 168.21 | -2.13 % | $ 12.6 B | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.81 | 0.34 % | $ 468 M | ||
|
AxoGen
AXGN
|
225 M | $ 31.01 | -4.99 % | $ 1.43 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 204.23 | 0.36 % | $ 14.4 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.76 | 9.09 % | $ 7.65 M | ||
|
Smith & Nephew plc
SNN
|
4.56 B | $ 31.76 | -2.67 % | $ 23.8 B | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.02 | -2.66 % | $ 851 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 331.18 | -0.34 % | $ 127 B | ||
|
Tactile Systems Technology
TCMD
|
330 M | $ 24.16 | -1.67 % | $ 553 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.61 | 3.37 % | $ 38 M | ||
|
TELA Bio
TELA
|
80.3 M | $ 0.7 | 11.11 % | $ 32.9 M | ||
|
TransMedics Group
TMDX
|
605 M | $ 107.91 | 2.97 % | $ 3.67 B | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 18.66 | -2.66 % | $ 1.27 B | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.68 | -0.21 % | $ 347 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 61.33 | -2.01 % | $ 90.8 B |